Overview

Location [1]
3q26.2
Protein [2]
MDS1 and EVI1 complex locus protein
Synonyms [1]
EVI1, RUSAT2, MDS1-EVI1, AML1-EVI-1, PRDM3, MDS1, KMT8E

MDS1 and EVI1 complex locus (MECOM) is a gene that encodes a protein that functions as a transcriptional regulator and oncoprotein. The protein may also have roles in hematopoiesis, apoptosis, development, cell differentiation, and cell proliferation. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.

MECOM is altered in 3.34% of all cancers with non-small cell lung carcinoma, melanoma, colorectal adenocarcinoma, uterine corpus neoplasm, and ovarian neoplasm having the greatest prevalence of alterations [3].

MECOM GENIE Cases - Top Diseases

The most common alterations in MECOM are MECOM Mutation (1.17%), MECOM Amplification (0.17%), MECOM G614Efs*30 (0.05%), MECOM E24K (0.02%), and MECOM P276L (0.01%) [3].

MECOM GENIE Cases - Top Alterations

Significance of MECOM in Diseases

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Acute Lymphoblastic Leukemia +

Chronic Myeloid Leukemia +

Chronic Myelomonocytic Leukemia +

Hodgkin Lymphoma +

Non-Hodgkin Lymphoma +

Multiple Myeloma +

Acute Biphenotypic Leukemia +

Burkitt Lymphoma +

Acute Leukemia +

Chronic Lymphocytic Leukemia +

Mantle Cell Lymphoma +

Follicular Lymphoma +

Marginal Zone Lymphoma +

Myelofibrosis +

Myeloproliferative Neoplasm +

Anaplastic Large Cell Lymphoma +

Lymphoma +

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

Juvenile Myelomonocytic Leukemia +

Myelodysplastic/Myeloproliferative Neoplasm +

Prolymphocytic Leukemia +

Lymphoplasmacytic Lymphoma +

Small Lymphocytic Lymphoma +

Diffuse Large B-Cell Lymphoma +

B-Cell Non-Hodgkin Lymphoma +

Double-Hit Lymphoma +

Lymphoblastic Lymphoma +

Plasma Cell Leukemia +

Primary Myelofibrosis +

Refractory Anemia With Excess Blasts +

Refractory Anemia With Excess Blasts-2 +

T-Cell Lymphoblastic Leukemia/Lymphoma +

T-Cell Non-Hodgkin Lymphoma +

Malignant Solid Tumor +

Acute Leukemia Of Ambiguous Lineage +

Acute Promyelocytic Leukemia +

Blastic Plasmacytoid Dendritic Cell Neoplasm +

Burkitt Leukemia +

Hematopoietic And Lymphoid Malignancy +

Mature T-Cell And NK-Cell Lymphoma/Leukemia +

Mature T-Cell And NK-Cell Neoplasm +

Myeloid Sarcoma +

Natural Killer Cell Lymphoblastic Leukemia/Lymphoma +

Peripheral T-Cell Lymphoma +

Refractory Anemia +

Secondary Myelofibrosis +

Small Lymphocytic Leukemia +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Rhabdomyosarcoma +

Neuroblastoma +

Acute Erythroid Leukemia +

Acute Megakaryoblastic Leukemia +

Acute Myeloid Leukemia With Myelodysplasia-Related Changes +

Acute Undifferentiated Leukemia +

Adult Acute Lymphoblastic Leukemia +

Adult T-Cell Leukemia/Lymphoma +

Aggressive Non-Hodgkin Lymphoma +

B-Cell Prolymphocytic Leukemia +

Chronic Myelomonocytic Leukemia-1 +

Desmoplastic Small Round Cell Tumor +

Ewing Sarcoma +

Mature B-Cell Lymphoma/Leukemia +

Mediastinal Large B-Cell Lymphoma +

Mixed Phenotype Acute Leukemia +

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +

Myeloma +

Plasma Cell Neoplasm +

Polycythemia Vera +

Refractory Anemia With Ring Sideroblasts +

Richter Syndrome +

Secondary Acute Myeloid Leukemia +

Secondary Myelodysplastic Syndrome +

T-Cell Prolymphocytic Leukemia +

T-Cell And NK-Cell Neoplasm +

Therapy-Related Acute Myeloid Leukemia +

Therapy-Related Myeloid Neoplasm +

Waldenstrom Macroglobulinemia +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.